157 related articles for article (PubMed ID: 37526849)
21. Registration of similar biological products--Singapore's approach.
Poh J; Tam KT
Biologicals; 2011 Sep; 39(5):343-5. PubMed ID: 21783381
[TBL] [Abstract][Full Text] [Related]
22. [Translational/regulatory science researches of NIHS for regenerative medicine and cellular therapy products].
Sato Y
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2014; (132):6-9. PubMed ID: 25707195
[TBL] [Abstract][Full Text] [Related]
23. [Chapter 2. Clinical trials of advanced therapy medicinal products: which future for the European regulation].
Mahalatchimy A; De Grove-Valdeyron N
J Int Bioethique Ethique Sci; 2018 Jul; 29(2):35-51. PubMed ID: 30767446
[TBL] [Abstract][Full Text] [Related]
24. Pharmacogenetic risk for adverse reactions to irinotecan in the major ethnic populations of Singapore: regulatory evaluation by the health sciences authority.
Sung C; Lee PL; Tan LL; Toh DS
Drug Saf; 2011 Dec; 34(12):1167-75. PubMed ID: 22077505
[TBL] [Abstract][Full Text] [Related]
25. Regulatory Framework, Challenges, and Initial Strategic Planning for Advanced Therapy Products (PTAs) Development in Brazil.
Fachel FNS; Schuh RS; Grudzinski PB; Teixeira HF; Baldo G; Matte U
Ther Innov Regul Sci; 2024 Jan; 58(1):21-33. PubMed ID: 37815738
[TBL] [Abstract][Full Text] [Related]
26. Towards a common framework for defining ancillary material quality across the development spectrum.
Ball O; Zylberberg C
Cytotherapy; 2019 Dec; 21(12):1234-1245. PubMed ID: 31837736
[TBL] [Abstract][Full Text] [Related]
27. Regulation of advanced therapy medicinal products in Europe and the role of academia.
Pearce KF; Hildebrandt M; Greinix H; Scheding S; Koehl U; Worel N; Apperley J; Edinger M; Hauser A; Mischak-Weissinger E; Dickinson AM; Lowdell MW
Cytotherapy; 2014 Mar; 16(3):289-97. PubMed ID: 24113428
[TBL] [Abstract][Full Text] [Related]
28. Regulation of cell-based therapeutic products intended for human applications in the EU.
Närhi MO; Nordström K
Regen Med; 2014 May; 9(3):327-51. PubMed ID: 24935044
[TBL] [Abstract][Full Text] [Related]
29. The regulation of cell therapy products in Canada.
Ridgway AA
Biologicals; 2015 Sep; 43(5):406-9. PubMed ID: 26141550
[TBL] [Abstract][Full Text] [Related]
30. First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes--Chapter 3: Porcine islet product manufacturing and release testing criteria.
Rayat GR; Gazda LS; Hawthorne WJ; Hering BJ; Hosking P; Matsumoto S; Rajotte RV
Xenotransplantation; 2016; 23(1):38-45. PubMed ID: 26923763
[TBL] [Abstract][Full Text] [Related]
31. Consideration of and expectations for the Pharmaceuticals, Medical Devices and Other Therapeutic Products Act in Japan.
Okada K; Koike K; Sawa Y
Regen Ther; 2015 Jun; 1():80-83. PubMed ID: 31245444
[TBL] [Abstract][Full Text] [Related]
32. Regulation of Cell and Gene Therapy Medicinal Products in Taiwan.
Lin YC; Wang PY; Tsai SC; Lin CL; Tai HY; Lo CF; Wu SI; Chiang YM; Liu LL
Adv Exp Med Biol; 2015; 871():181-94. PubMed ID: 26374219
[TBL] [Abstract][Full Text] [Related]
33. [Regulatory science research to facilitate the development of cell/tissue-processed products].
Sato Y; Tsutsumi H; Sawada R; Suzuki T; Yasuda S
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2013; (131):16-9. PubMed ID: 24340665
[TBL] [Abstract][Full Text] [Related]
34. Thoughts on Chemistry, Manufacturing, and Control of Cell Therapy Products for Clinical Application.
Wei W; Luo J
Hum Gene Ther; 2019 Feb; 30(2):119-126. PubMed ID: 30311789
[TBL] [Abstract][Full Text] [Related]
35. Safety and quality assessment of 175 illegal sexual enhancement products seized in red-light districts in Singapore.
Low MY; Zeng Y; Li L; Ge XW; Lee R; Bloodworth BC; Koh HL
Drug Saf; 2009; 32(12):1141-6. PubMed ID: 19916581
[TBL] [Abstract][Full Text] [Related]
36. 19th Annual Meeting of the Safety Pharmacology Society: regulatory and safety perspectives for advanced therapy medicinal products (cellular and gene therapy products).
Cavero I; Seimetz D; Koziel D; Zimmermann WH; Holzgrefe HH
Expert Opin Drug Saf; 2020 May; 19(5):553-558. PubMed ID: 32163309
[TBL] [Abstract][Full Text] [Related]
37. Regulatory Frameworks for Gene and Cell Therapies in Japan.
Maeda D; Yamaguchi T; Ishizuka T; Hirata M; Takekita K; Sato D
Adv Exp Med Biol; 2015; 871():147-62. PubMed ID: 26374217
[TBL] [Abstract][Full Text] [Related]
38. Regulation Policy for Cell and Tissue Therapies in Australia.
Sturm M
Tissue Eng Part A; 2015 Dec; 21(23-24):2797-801. PubMed ID: 26096750
[TBL] [Abstract][Full Text] [Related]
39. Report of the International Regulatory Forum on Human Cell Therapy and Gene Therapy Products.
Hayakawa T; Harris I; Joung J; Kanai N; Kawamata S; Kellathur S; Koga J; Lin YC; Maruyama Y; McBlane J; Nishimura T; Renner M; Ridgway A; Salmikangas P; Sakamoto N; Sato D; Sato Y; Toda Y; Umezawa A; Werner M; Wicks S
Biologicals; 2016 Sep; 44(5):467-79. PubMed ID: 27461129
[TBL] [Abstract][Full Text] [Related]
40. Regulatory issues in cell-based therapy for clinical purposes.
Casaroli-Marano RP; Tabera J; Vilarrodona A; Trias E
Dev Ophthalmol; 2014; 53():189-200. PubMed ID: 24732772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
